Company: INMB
Filing Date: 2025-06-16
Form Type: S-8
Source: 0001213900-25-054427
Chunk: 6

Company: Inmune Bio, Inc.
Filing Date: 2025-06-16
Form: S-8
Chunk 6
---
 information in the document having the later date shall modify or supersede the earlier statement.

As permitted by the rules and regulations of the SEC, the Registration Statement of which this reoffer prospectus forms a part includes additional information not contained in this reoffer prospectus. You may read the Registration Statement and the other reports we file with the SEC at the SEC’s website or at our website as described above under the heading “Incorporation of Certain Documents by Reference.”

In this reoffer prospectus, the “Company,” “we,” “us” and “our” refer to INmune Bio Inc. and its subsidiaries.

Company Overview

Our objective is to develop and commercialize our product candidates
to treat diseases where the innate immune system is dysfunctional causing or contributing to the patient’s disease. Innate immune
dysfunction can occur for a variety of reasons including genetics, lifestyle, and other factors. However, age plays a significant role
in the development of immune dysfunction. Innate immune dysfunction can be seen in cancer where natural killer cells are impaired and
facilitate a tumor’s evasion of the immune system and subsequent disease progression. Chronic inflammation is implicated in neurologic
and metabolic diseases where it impairs the innate immune system. Our primary focus continues to be treatment of cancer with INKmune and
treatment of Alzheimer’s Disease (“AD”) and Treatment Resistant Depression (“TRD”) with XPro1595 (“XPro”).
We have added CORDStrom, a pooled, human umbilical cord mesenchymal stem cell product to treat recessive dystrophic epidermolysis bullosa
(“RDEB”), a pediatric orphan disease caused by mutations in the COL7A1 gene that results in a debilitating disease of skin
blistering, dysphagia and failure to thrive with chronic wound problems that often results in fatal squamous cell carcinoma.

XPro, targets AD and TRD. XPro for AD has completed Phase I trials
and a Phase II trial has completed enrollment of patients at clinical sites in the United Kingdom, European Union (“EU”),
Australia and Canada. Patients are currently being treated with XPro for early AD as part of that clinical trial. TRD is being prepared
for Phase II trials. We expect to start a pivotal global registration trial in patients with AD after the results of the Phase II trial
have been analyzed. The INKmune program is in an open label Phase II trial in metastatic castrate resistant prostate cancer